Robert F. Leibenluft Esq.

Hogan Lovells
Leibenluft, Robert F.

Bob Leibenluft is a Partner in the Washington, D.C. office of Hogan Lovells. Mr. Leibenluft's practice is devoted entirely to health and antitrust matters, including counseling and litigation regarding antitrust issues in the health, medical device, and pharmaceutical industries.

Upon completing law school, Mr. Leibenluft worked as an attorney advisor in the Federal Trade Commission (FTC)'s Office of Policy Planning, concentrating on health and antitrust matters. In 1981, he joined Hogan & Hartson (now Hogan Lovells) and became a partner in the firm in 1989. He practiced health law at Hogan & Hartson until January 1996 when he rejoined the FTC as Assistant Director for Health Care in the FTC’s Bureau of Competition.

As head of the Health Care Division, he supervised a 25-30 person staff engaged in the review of mergers, acquisitions, and joint ventures involving hospitals, physicians, and other healthcare providers, as well as conduct in the healthcare and pharmaceutical industries. While at the FTC, he supervised the 1996 revisions of the FTC and DOJ Statements of Antitrust Enforcement Policy in Health Care in which the Agencies first addressed clinical integration. He rejoined Hogan & Hartson in September 1998.

Mr. Leibenluft is an inaugural fellow of the American Health Lawyers Association, where he previously served as a Vice President and member of the Board of Directors. He is a former Chair of the ABA Antitrust Section Joint Conduct Committee, Health and Pharmaceuticals Committee and State Enforcement Committee. He is Chair of the Board of Directors of HCI3, the parent company of Prometheus Payment Inc. and Bridges to Excellence. He is also an adjunct law professor at the George Washington Law School where he teaches a course on Antitrust in the Health Care Sector.

Mr. Leibenluft received his B.A. from Yale University and later received his J.D. from the University of California, Berkeley.


He is a co-author of Bloomberg BNA Corporate Practice Portfolio Series No. 90, Antitrust Compliance.